ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Zeria Pharmaceutical Co., Ltd. ?
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 7.64% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 8.64% signifying low profitability per unit of shareholders funds
2
Negative results in Jun 25
- ROCE(HY) Lowest at 8.05%
- INTEREST COVERAGE RATIO(Q) Lowest at 2,682.93
- NET SALES(Q) Lowest at JPY 19,489.79 MM
3
With ROCE of 11.39%, it has a very attractive valuation with a 1.18 Enterprise value to Capital Employed
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of -19.06%, its profits have risen by 38.3% ; the PEG ratio of the company is 0.3
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -19.06% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Zeria Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Zeria Pharmaceutical Co., Ltd. for you?
Low Risk, Low Return
Absolute
Risk Adjusted
Volatility
Zeria Pharmaceutical Co., Ltd.
-19.06%
-0.20
20.97%
Japan Nikkei 225
28.54%
1.11
25.75%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
7.64%
EBIT Growth (5y)
24.92%
EBIT to Interest (avg)
21.87
Debt to EBITDA (avg)
2.65
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
0.62
Tax Ratio
21.01%
Dividend Payout Ratio
20.85%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.96%
ROE (avg)
8.64%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
1.22
EV to EBIT
10.39
EV to EBITDA
6.42
EV to Capital Employed
1.18
EV to Sales
1.45
PEG Ratio
0.28
Dividend Yield
NA
ROCE (Latest)
11.39%
ROE (Latest)
11.32%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend3What is working for the Company
DEBT-EQUITY RATIO
(HY)
Lowest at 21.05 %
CASH AND EQV(HY)
Highest at JPY 43,570.89 MM
-20What is not working for the Company
ROCE(HY)
Lowest at 8.05%
INTEREST COVERAGE RATIO(Q)
Lowest at 2,682.93
NET SALES(Q)
Lowest at JPY 19,489.79 MM
INTEREST(Q)
Highest at JPY 121.87 MM
OPERATING PROFIT(Q)
Lowest at JPY 3,269.57 MM
OPERATING PROFIT MARGIN(Q)
Lowest at 16.78 %
PRE-TAX PROFIT(Q)
Lowest at JPY 1,659.6 MM
NET PROFIT(Q)
Lowest at JPY 1,090.75 MM
EPS(Q)
Lowest at JPY 24.75
Here's what is working for Zeria Pharmaceutical Co., Ltd.
Debt-Equity Ratio
Lowest at 21.05 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Cash and Eqv
Highest at JPY 43,570.89 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for Zeria Pharmaceutical Co., Ltd.
Pre-Tax Profit
At JPY 1,659.6 MM has Fallen at -69.61%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (JPY MM)
Net Profit
At JPY 1,090.75 MM has Fallen at -74.11%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (JPY MM)
Interest Coverage Ratio
Lowest at 2,682.93
in the last five periodsMOJO Watch
The company's ability to manage interest payments is deteriorating
Operating Profit to Interest
Net Sales
Lowest at JPY 19,489.79 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (JPY MM)
Net Sales
Fallen at -9.16%
Year on Year (YoY)MOJO Watch
Near term sales trend is negative
Net Sales (JPY MM)
Interest
Highest at JPY 121.87 MM
in the last five periods and Increased by 7.45% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (JPY MM)
Operating Profit
Lowest at JPY 3,269.57 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (JPY MM)
Operating Profit Margin
Lowest at 16.78 %
in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Pre-Tax Profit
Lowest at JPY 1,659.6 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (JPY MM)
Net Profit
Lowest at JPY 1,090.75 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (JPY MM)
EPS
Lowest at JPY 24.75
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (JPY)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
